Product Information
BUMETANIDE 1 MG TABLET is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.1585 per EA under NDC 68382052605. Its NADAC has been published 267 times since May 27, 2020.
FDA first approved this application on Apr 30, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the bumetanide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382052605
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
6/18/2025
Active Ingredients
BUMETANIDEApproval Type
Generic (ANDA)
FDA Application
ANDA202900FDA Approved
4/30/2018
TE Code
AB
On Market Since
5/1/2018
Pharmacological Classes
Price Statistics
The NADAC for BUMETANIDE 1 MG TABLET has been published 267 times since May 27, 2020, and over the history we have for it it has declined 60.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1585 per EA |
|---|---|
| All-time high | $0.3966 (Jun 10, 2020) |
| All-time low | $0.1247 (Nov 20, 2024) |
| Median price | $0.2169 |
| Average price | $0.2256 |
| Largest weekly change | +76.2% (Aug 21, 2024) |
| Weeks tracked | 267 |
| Tracking since | May 27, 2020 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-24.5%
5Y
-38.5%
All
-60.0%
Last surveyed Jul 2, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 32% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bumetanide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Loop Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUMETANIDE 1 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUMETANIDE 1 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.1585 per EA (NDC 68382052605), effective Jul 2, 2025.
How has the price of BUMETANIDE 1 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUMETANIDE 1 MG TABLET has declined 60.0%. It has been tracked across 267 weekly CMS publications since May 27, 2020.
What are the highest and lowest recorded NADAC prices for BUMETANIDE 1 MG TABLET?
Since May 27, 2020, the NADAC for BUMETANIDE 1 MG TABLET has ranged from a low of $0.1247 (Nov 20, 2024) to a high of $0.3966 (Jun 10, 2020), with a median of $0.2169 per EA.
Are there cheaper alternatives to BUMETANIDE 1 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUMETANIDE 1 MG TABLET, is $0.1079 per EA — about 32% below BUMETANIDE 1 MG TABLET.
Who manufactures BUMETANIDE 1 MG TABLET?
BUMETANIDE 1 MG TABLET (NDC 68382052605) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.